Tag: NASDAQ JAGX

Business

Jaguar Health Inc (NASDAQ: JAGX) Announces Conclusion of Investigator-Originated Stage 2 HALT-D Study

Jaguar Health Inc (NASDAQ: JAGX) completes the third-party, investigator-initiated Stage 2 HALT-D study assessing the efficacy of Mytesi┬« (crofelemer) for the indicative respite of diarrhea in HER2 progressive breast cancer patients getting chemotherapy with trastuzumab, pertuzumab, and docetaxel. Synopsis of study fallouts proffered by the third-party gumshoes to December 2021 […]